X
AbbVie pulls phase 3 ADC trials in glioblastoma after survival miss
https://pharmaphorum.com/news/abbvie-pulls-phase-3-adc-trials-in-glioblastoma-after-survival-miss/
glioblastoma
Kick-starting innovation in Glioblastoma
Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
Celgene hopes device + drug can tackle aggressive brain tumours
Novocure’s Optune will be tested alongside investigational Celgene drug marizomib.
IBM Watson impresses in brain tumour analysis
Watson for Genomics produces treatment insights for glioblastoma in 10 minutes.
Head patch device Optune improves brain cancer survival
Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
Digital Health Round-up – Is AI the future of cancer drug development?
Does artificial intelligence hold the key to cancer drug R&D?
BERG begins trial for AI-engineered brain cancer drug
Drug will be tested as a monotherapy for glioblastoma multiforme.
Electrical patch device shows promise against ovarian cancer
Novocure’s Optune device shown to be safe and tolerable in recurrent ovarian cancer.